You are not logged in.

Bevacizumab for the treatment of high-grade glioma

Khasraw, Mutsafa, Simeonovic, Marcelle and Grommes, Christian 2012, Bevacizumab for the treatment of high-grade glioma, Expert opinion on biological therapy, vol. 12, no. 8, pp. 1101-1111, doi: 10.1517/14712598.2012.694422.

Attached Files
Name Description MIMEType Size Downloads

Title Bevacizumab for the treatment of high-grade glioma
Author(s) Khasraw, MutsafaORCID iD for Khasraw, Mutsafa orcid.org/0000-0003-3249-9849
Simeonovic, Marcelle
Grommes, Christian
Journal name Expert opinion on biological therapy
Volume number 12
Issue number 8
Start page 1101
End page 1111
Total pages 11
Publisher Informa Healthcare
Place of publication London, England
Publication date 2012-08
ISSN 1354-3776
1744-7674
Keyword(s) anti-angiogenic therapy
high-grade glioma
glioblastoma
bevacizumab
Summary Introduction: Gliomas are highly vascular and rich in vascular endothelial growth factor (VEGF) that promotes angiogenesis. Bevacizumab is a monoclonal antibody against VEGF inhibiting angiogenesis by preventing receptor activation. Phase II clinical trials using bevacizumab in both newly diagnosed and recurrent high-grade glioma (HGG) showed promising results.

Areas covered:
This is a review of clinical trials investigating bevacizumab in newly diagnosed and recurrent HGGs with a focus on outcome results. A future perspective about the expected role of bevacizumab is given. Bevacizumab efficacy, safety and tolerability, the combination of radiation and bevacizumab as well as the use of bevacizumab to treat pseudoprogression are discussed. Further criteria of response evaluation needed to be adjusted in the age of anti-angiogenic therapy and this will be discussed.

Expert opinion:
Bevacizumab has been shown to be safe and tolerable in HGG. In the recurrent disease setting, bevacizumab alone might be sufficient for a clinical benefit and is currently approved as a single agent for this indication. While clinical trials demonstrate a prolonged progression-free survival in bevacizumab-treated HGG, a benefit on OS has not been demonstrated yet. Bevacizumab has also been introduced into other settings in neuro-oncology including concurrent administration with re-irradiation for recurrent HGG.



Language eng
DOI 10.1517/14712598.2012.694422
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2012, Informa UK
Persistent URL http://hdl.handle.net/10536/DRO/DU:30046304

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in TR Web of Science
Scopus Citation Count Cited 12 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 196 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 30 Jul 2012, 13:35:06 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.